Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

MediciNova, Inc. (MNOV)

2.46   -0.01 (-0.4%) 01-27 16:00
Open: 2.44 Pre. Close: 2.47
High: 2.49 Low: 2.41
Volume: 32,551 Market Cap: 121(M)

Technical analysis

as of: 2023-01-27 4:46:20 PM
Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected.
Target: Six months: 3.01     One year: 3.51
Support: Support1: 2.19    Support2: 1.95
Resistance: Resistance1: 2.57    Resistance2: 3.01
Pivot: 2.43
Moving Average: MA(5): 2.46     MA(20): 2.36
MA(100): 2.23     MA(250): 2.38
MACD: MACD(12,26): 0     Signal(9): 0
Stochastic oscillator: %K(14,3): 68.9     %D(3): 73.7
RSI: RSI(14): 56.4
52-week: High: 3.18  Low: 1.95
Average Vol(K): 3-Month: 87 (K)  10-Days: 24 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ MNOV ] has closed below upper band by 40.8%. Bollinger Bands are 42.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 2.49 - 2.51 2.51 - 2.52
Low: 2.38 - 2.39 2.39 - 2.41
Close: 2.43 - 2.46 2.46 - 2.48

Company Description

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction. Its product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic diseases, including nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. The company has collaboration agreements with Kissei Pharmaceutical Co., Ltd.; Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals Ltd.; and Meiji Seika Kaisha Ltd. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California.

Headline News

Thu, 12 Jan 2023
MediciNova Announces Completion of Enrollment in the Phase 2 Clinical Trial Evaluating MN-166 (ibudilast) for Treatment of Recurrent and Newly Diagnosed Glioblastoma - Yahoo Finance

Wed, 11 Jan 2023
MediciNova to get Canadian patent linked to potential skin disorder ... - Seeking Alpha

Tue, 10 Jan 2023
Should You Buy Medicinova Inc (MNOV) Stock Tuesday Morning? - InvestorsObserver

Thu, 05 Jan 2023
MediciNova to Meet with U.S. FDA to Discuss Clinical Development of a Parenteral Formulation of MN-166 (ibudilast) - Yahoo Finance

Tue, 06 Dec 2022
MediciNova Announces Additional Positive Results Regarding the Effects of MN-001 (tipelukast) on Serum Lipid Panel in Type 2 Diabetes and NAFLD Patients Presented at IDF 2022 Congress, the Annual Meeting of the International Diabetes Federation - Yahoo Finance

Tue, 29 Nov 2022
13 Best Biotech Penny Stocks To Buy Now - Yahoo Finance

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 49 (M)
Shares Float 42 (M)
% Held by Insiders 2.9 (%)
% Held by Institutions 25.2 (%)
Shares Short 529 (K)
Shares Short P.Month 669 (K)

Stock Financials

EPS -0.28
EPS Est Next Qtl 1.86
EPS Est This Year -0.35
EPS Est Next Year -0.35
Book Value (p.s.) 1.49
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -10
Return on Equity (ttm) -16.5
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0.08
Sales Per Share 0
EBITDA (p.s.) -0.28
Qtrly Earnings Growth 0
Operating Cash Flow -13 (M)
Levered Free Cash Flow -8 (M)

Stock Valuations

PE Ratio -9.05
PEG Ratio 0
Price to Book value 1.65
Price to Sales 0
Price to Cash Flow -9.63

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.